Recombinant FVIII-Fc fusion protein (Chengdu Rongsheng)
重组人凝血因子VIII-Fc融合蛋白（成都蓉生）
Report date: 2025/12/08 20:00:58
Base Information
Drug NameRecombinant FVIII-Fc fusion protein (Chengdu Rongsheng)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesChengdu Rongsheng Pharmaceuticals Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesChengdu Rongsheng Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A